GuruFocus.com1d agobearish
AstraZeneca Stock Plunges 7.7% on Reported $400 Billion Merger TalksInvestors questioned whether combining AstraZeneca with Bristol Myers would strengthen growth enough to justify the financial and regulatory risks.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
490last 24h
2474last 7d
479● bullish (7d)
251● bearish (7d)
197publishers
Pharmaceutical Technology1d agobearish
AstraZeneca shares slump after $400bn BMS merger rumoursOne of the largest global pharma companies would be created if a deal were to materialise.
Barrons.com2d agobearish
Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZenecaThe merger would be one of the biggest pharma deals ever. AstraZeneca’s market capitalization stood at $264 billion as of Friday’s close, while Bristol Myers Squibb had a total valuation of $133 billion.
The Wall Street Journal2d agobearish
AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger TalksIf maintained until close, the decline would be the stock’s biggest one-day percentage fall since the day of the 2024 U.S. presidential election.